Results from the world’s largest comprehensive study of hypertrophic cardiomyopathy patients are in—and they’re providing cardiologists with a wealth of previously unknown information about the disease.

The 2010s saw a decrease in age-adjusted mortality associated with heart disease, according to a JAMA Cardiology report, but a concomitant rise in heart failure-related deaths and increase in the global population of adults over 65 actually resulted in an increase in the number of fatalities attributed to CVD.

Research published in JACC: Heart Failure Nov. 6 uncovered a worrying statistic in cardiology: Older patients who are hospitalized for heart failure could experience as much as a 12% increase in the number of HF-exacerbating medications they’re prescribed between admission and hospital discharge.

Research out of Brigham and Women’s Hospital in Boston found heart failure patients who self-identify as black, Latinx or female are less likely to be admitted to the hospital’s cardiology department, suggesting admission bias might be a partial contributor to known racial disparities in HF outcomes.

The combo drug sacubitril/valsartan was associated with early improvements in health status in a study of nearly 4,000 patients with HFrEF.

Metformin use is linked to a lower risk of hospitalization for heart failure in patients with type 2 diabetes, a paper in the Journal of the American Heart Association confirms.

A novel machine learning algorithm improved patient selection for CRT in a study of nearly 1,000 heart failure patients, representing an opportunity to optimize care and spare certain individuals from a pricey procedure that might not benefit them.

Pharmaceutical company AstraZeneca announced Oct. 21 that its drug Farxiga—or dapagliflozin—was approved by the FDA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.